<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01237600</url>
  </required_header>
  <id_info>
    <org_study_id>447/2550(EC2)</org_study_id>
    <nct_id>NCT01237600</nct_id>
  </id_info>
  <brief_title>Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction</brief_title>
  <official_title>Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to elucidate the appropriate condition of  developing
      cultivated corneal epithelial graft and evaluate the surgical outcome of transplantation of
      the cultivated corneal epithelial stem cell in the patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ocular surface damage caused by severe ocular surface diseases, particularly thermal and
      chemical burn or Stevens-Johnson syndrome result in corneal epithelial defect, corneal
      vascularization, corneal conjunctivalization and loss of transparency.  Corneal limbal stem
      cell transplantation has been demonstrated to improve the outcome of ocular surface
      reconstruction. However, the conventional management of allograft limbal transplantation
      generally has unsatisfactory outcome because of high risk of rejection and requires
      long-life immunosuppressive medications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Ocular surface status (signs of limbal deficiency and immunopathological markers)</measure>
    <time_frame>Three years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Ocular Surface Damage</condition>
  <condition>Limbal Deficiency</condition>
  <arm_group>
    <arm_group_label>Cultivated limbal transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cultivated limbal transplantation</intervention_name>
    <description>Cultivated corneal epithelial stem cell transplantation. Autograft, Living related allograft, and Cadaveric allograft</description>
    <arm_group_label>Cultivated limbal transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral/Bilateral limbal stem cell deficiency proved by specific clinical features
             and impression cytology result

        Exclusion Criteria:

          -  Age under 18

          -  Active ocular infection, Severe dry eye, Uncontrolled glaucoma

          -  Immunocompromised host

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pinnita Prabhasawat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnita Prabhasawat, MD</name>
      <address>
        <city>Bangkok</city>
        <zip>10300</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pinnita Prabhasawat, MD</last_name>
      <phone>662-419-7000</phone>
      <phone_ext>8033</phone_ext>
      <email>sippb@mahidol.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>Suksri Chotikavanich, MD</last_name>
      <phone>662-419-7000</phone>
      <phone_ext>8033</phone_ext>
      <email>suksri_c@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <lastchanged_date>November 8, 2010</lastchanged_date>
  <firstreceived_date>November 8, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Pinnita Prabhasawat, MD; Nattaporn Tesavibul, MD; Suksri Chotikavanich, MD</name_title>
    <organization>Mahidol university</organization>
  </responsible_party>
  <keyword>Ocular surface damage</keyword>
  <keyword>Limbal deficiency</keyword>
  <keyword>Cultivated corneal epithelial stem cell transplantation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
</clinical_study>
